Ionis Pharmaceuticals IONS Amortized cost of available-for-sale debt securities, current
Amortized cost of available-for-sale debt securities, current at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's amortized cost of available-for-sale debt securities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's amortized cost of available-for-sale debt securities, current?
- Ionis Pharmaceuticals (IONS) reported amortized cost of available-for-sale debt securities, current of $1.12B in Q1 2026.
- How has Ionis Pharmaceuticals's amortized cost of available-for-sale debt securities, current changed year-over-year?
- Ionis Pharmaceuticals's amortized cost of available-for-sale debt securities, current decreased by 9.4% year-over-year, from $1.23B to $1.12B.
- What is the long-term trend for Ionis Pharmaceuticals's amortized cost of available-for-sale debt securities, current?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's amortized cost of available-for-sale debt securities, current has grown at a 26.7% compound annual growth rate (CAGR), from $612.56M to $1.58B.
- What does amortized cost of available-for-sale debt securities, current mean?
- The book value of current debt securities before adjusting for market price changes.
- How do you interpret amortized cost of available-for-sale debt securities, current?
- Changes reflect shifts in the company's short-term cash deployment strategy into fixed-income securities.
- How does amortized cost of available-for-sale debt securities, current compare across companies?
- Standard reporting for treasury assets across the life sciences industry.